Drawing for CRESCENDO BIOLOGICS

USPTO serial 79209645

CRESCENDO BIOLOGICS

Reviewed by CopyMark Law Group

Reg. 5488713Status 706Registered
Filing date
Status date
Registration date
Jun 12, 2018
Examiner
LEE, JEANIE H
Law office
Historical data usage

What this means

This trademark is registered with the USPTO. Monitoring new filings can help you catch lookalike marks early.

Need help with CRESCENDO BIOLOGICS?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Christopher J. Schulte

Christopher J. Schulte Merchant & Gould P.C.P.O. Box 2910Minneapolis, MN 55402-0910United States

Goods and services

ClassDescriptionStatusFirst use
001Chemicals used in industry and science; [ chemicals for laboratory research purposes, namely, chemical tests kits for in vitro testing; ] antibodies and antibody fragments for scientific and laboratory use in the nature of biochemical, namely, monoclonal antibodies for in vitro scientific or research use; biochemical, namely, monoclonal antibodies and antibody fragments for scientific and laboratory use; antibodies and antibody fragments all being protein in raw material form for scientific research purposes; antibody reagents used for the detection of antigens in cell and tissue analysis for scientific and laboratory in vitro diagnostic use; antibodies and antibody fragments all being proteins for industrial use in the discovery, preclinical and clinical development of therapeutic productsACTIVE—
005Pharmaceutical preparations for the treatment of cancer, [ autoimmune diseases, inflammatory conditions, allergies and allergic conditions, hypersensitivity reactions, infections, organ transplant rejection, tissue transplant rejection, cardiovascular diseases, neurological disorders, degenerative disorders, metabolic disorders, dermatological diseases; ] veterinary preparations for the treatment of cancer, [ autoimmune diseases, inflammatory conditions, allergies and allergic conditions, hypersensitivity reactions, infections, organ transplant rejection, tissue transplant rejection, cardiovascular diseases, neurological disorders, degenerative disorders, metabolic disorders, dermatological diseases; ] therapeutic preparations in the nature of antibodies and antibody fragments for medical and veterinary purposes, namely, therapeutic pharmaceutical preparations for the treatment of cancer, [ autoimmune diseases, inflammatory conditions, allergies and allergic conditions, hypersensitivity reactions, infections, organ transplant rejection, tissue transplant rejection, cardiovascular diseases, neurological disorders, degenerative disorders, metabolic disorders, dermatological diseases; ] antibodies, being pharmaceutical preparations for the treatment of cancer, [ autoimmune diseases, inflammatory conditions, allergies and allergic conditions, hypersensitivity reactions, infections, organ transplant rejection, tissue transplant rejection, cardiovascular diseases, neurological disorders, degenerative disorders, metabolic disorders, dermatological diseases; antibody fragments, being pharmaceutical preparations for the treatment of cancer, autoimmune diseases, inflammatory conditions, allergies and allergic conditions, hypersensitivity reactions, infections, organ transplant rejection, tissue transplant rejection, cardiovascular diseases, neurological disorders, degenerative disorders, metabolic disorders, dermatological diseases; ] monoclonal antibody therapies for therapeutic purposes, being pharmaceutical preparations for the treatment of cancer, [ autoimmune diseases, inflammatory conditions, allergies and allergic conditions, hypersensitivity reactions, infections, organ transplant rejection, tissue transplant rejection, cardiovascular diseases, neurological disorders, degenerative disorders, metabolic disorders, dermatological diseases; ] antibodies and antibody fragments, being pharmaceutical preparations for the treatment of cancer, [ autoimmune diseases, inflammatory conditions, allergies and allergic conditions, hypersensitivity reactions, infections, organ transplant rejection, tissue transplant rejection, cardiovascular diseases, neurological disorders, degenerative disorders, metabolic disorders, dermatological diseases, for medical and veterinary diagnostics; antibodies and antibody fragments, being pharmaceutical preparations for the treatment of cancer, autoimmune diseases, inflammatory conditions, allergies and allergic conditions, hypersensitivity reactions, infections, organ transplant rejection, tissue transplant rejection, cardiovascular diseases, neurological disorders, degenerative disorders, metabolic disorders, dermatological diseases, for use in the discovery, preclinical and clinical development of therapeutic products; antibodies and antibody fragments, being pharmaceutical preparations for the treatment of cancer, autoimmune diseases, inflammatory conditions, allergies and allergic conditions, hypersensitivity reactions, infections, organ transplant rejection, tissue transplant rejection, cardiovascular diseases, neurological disorders, degenerative disorders, metabolic disorders, dermatological diseases, ] for use in the manufacture of therapeutic productsACTIVE—
040Treatment and transformation of materials for others, namely the custom manufacture of chemicals, biologicals, antibodies and antibody fragments; contract manufacturing services in the field of chemicals, biologicals, antibodies and antibody fragments; services for the custom manufacture of medical therapies using antibodies and antibody fragmentsACTIVE—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Aug 13, 2026INNPPARTIAL INVALIDATION PROCESSED BY THE IB—
Jul 19, 2026INPSPARTIAL INVALIDATION OF REG EXT PROTECTION SENT TO IB—
Jul 19, 2026INPCINVALIDATION PROCESSED—
Dec 24, 2025INPRPARTIAL INVALIDATION OF REG EXT PROTECTION CREATED—
Jun 3, 2025LIMNLIMITATION FROM THE IB EXAMINED, NO ACTION IS NEEDED—
Apr 24, 2025NA71NOTICE OF ACCEPTANCE OF SEC. 71 - E-MAILED—
Apr 24, 202571AGREGISTERED-SEC.71 ACCEPTED—
Apr 21, 2025APRECASE ASSIGNED TO POST REGISTRATION PARALEGAL—
Dec 4, 2024ES71TEAS SECTION 71 RECEIVED—
Nov 8, 2024RHRDRESTRICTION OF HOLDER'S RIGHT OF DISPOSAL RECEIVED—
Oct 27, 2023LIMNLIMITATION FROM THE IB EXAMINED, NO ACTION IS NEEDED—
Aug 19, 2023RHRDRESTRICTION OF HOLDER'S RIGHT OF DISPOSAL RECEIVED—
Jun 12, 2023REM3COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED—
Oct 6, 2018FINOFINAL DECISION TRANSACTION PROCESSED BY IB—
Sep 18, 2018FICSFINAL DISPOSITION NOTICE SENT TO IB—
Sep 18, 2018FIMPFINAL DISPOSITION PROCESSED—
Sep 12, 2018FICRFINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB—
Jun 12, 2018R.PRREGISTERED-PRINCIPAL REGISTERYour trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive.
Mar 27, 2018NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Mar 27, 2018PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Mar 24, 2018GPNXNOTIFICATION PROCESSED BY IB—
Mar 7, 2018OPNSNOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB—
Mar 7, 2018NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
Mar 7, 2018OP2RNOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB—
Feb 16, 2018CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Feb 14, 2018TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Feb 14, 2018CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Feb 14, 2018ERFRTEAS REQUEST FOR RECONSIDERATION RECEIVED—
Feb 1, 2018ARAAATTORNEY/DOM.REP.REVOKED AND/OR APPOINTEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Feb 1, 2018REAPTEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED—
Jan 12, 2018CNFRFINAL REFUSAL MAILEDA final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon.
Jan 11, 2018CNFRFINAL REFUSAL WRITTENA final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon.
Dec 20, 2017TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Dec 19, 2017CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Dec 19, 2017TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Dec 7, 2017NREPNEW REPRESENTATIVE AT IB RECEIVED—
Jul 14, 2017RFNTREFUSAL PROCESSED BY IB—
Jun 23, 2017RFCSNON-FINAL ACTION MAILED - REFUSAL SENT TO IB—
Jun 23, 2017RFRRREFUSAL PROCESSED BY MPU—
Jun 16, 2017MAFRAPPLICATION FILING RECEIPT MAILED—
Jun 15, 2017RFCRNON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW—
Jun 14, 2017CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Jun 12, 2017DOCKASSIGNED TO EXAMINER—
Jun 12, 2017NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Jun 8, 2017REPRSN ASSIGNED FOR SECT 66A APPL FROM IB—

Frequently asked questions

Related guidance